WuXi Biologics (Cayman) PEG Ratio

The latest PEG ratio for WXIBF is 989.14. That is above the Healthcare sector average of 12.15. Investors often review this figure alongside WuXi Biologics (Cayman)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, WXIBF currently prints 989.14 for PEG ratio, while the sector average sits near 12.15. That is roughly 8039.1% above the sector mean. Large gaps often invite a closer look at WuXi Biologics (Cayman)'s growth, margins, and balance sheet.

A PEG ratio of 989.14 for WuXi Biologics (Cayman) is not 'good' or 'bad' on its own. Compare it with the peer average (12.15) and with WXIBF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting WXIBF's PEG ratio (989.14), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack WuXi Biologics (Cayman)'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.